Does Aetna (CVS Health) Cover Lunesta (Eszopiclone)?

What Aetna's Formulary Says About Lunesta

Aetna (CVS Health) commercial formularies place eszopiclone on tier 3 or tier 4 in the majority of plan designs, meaning the drug is covered but carries a higher cost-share than generic alternatives. The brand-name Lunesta is rarely placed on tier 1 or tier 2. Generic eszopiclone, which the FDA approved in 2014, appears on tier 1 or tier 2 on many Aetna plans, which is why step therapy almost always begins with the generic before brand-name Lunesta is authorized. [1]

Formulary placement changes annually during Aetna's CVS Caremark benefit review cycle. Members should pull their specific Summary of Benefits and Coverage (SBC) or call the pharmacy benefits number on their insurance card each January to confirm the current tier assignment. A tier-3 cost-share on a typical Aetna commercial plan runs $45 to $75 per 30-day fill; tier 4 can reach $90 to $120 per fill before meeting a deductible. [2]

The FDA-approved indication for eszopiclone is the treatment of insomnia, defined in the original 2004 New Drug Application review as difficulty with sleep onset or sleep maintenance. [3] Aetna's coverage policy mirrors that indication closely. Prescriptions written for off-label purposes, including shift-work sleep disorder or anxiety-related insomnia without a formal diagnosis code of insomnia (ICD-10 G47.00), are at higher risk of denial on first submission.

Eszopiclone is the S-enantiomer of zopiclone and acts as a positive allosteric modulator at GABA-A receptors, specifically at benzodiazepine-binding sites. [4] Its receptor selectivity profile differs from classic benzodiazepines, which is the pharmacological basis physicians use in PA justification letters to explain why a benzodiazepine trial is not clinically appropriate for a specific patient.

Aetna's Prior-Authorization Criteria for Eszopiclone

Prior authorization for Lunesta through Aetna (CVS Health) is classified as moderate-to-high difficulty, meaning the clinical threshold is higher than for many other insomnia agents. To satisfy Aetna's standard PA criteria, a prescriber must typically document all of the following. [5]

First, a confirmed diagnosis of chronic insomnia disorder (G47.00 or G47.09) with symptom duration of at least four weeks. Second, documentation that non-pharmacological interventions, specifically cognitive behavioral therapy for insomnia (CBT-I), were either tried and failed or are not accessible within a reasonable geographic or cost radius. The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline names CBT-I as the first-line treatment for chronic insomnia disorder in adults, stating: "We recommend that clinicians use cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment for chronic insomnia disorder in adults." [6] Aetna's medical policy cites the AASM guideline as the clinical basis for requiring CBT-I documentation.

Third, evidence that at least one formulary-preferred sedative-hypnotic was tried at an adequate dose for at least 30 days or was contraindicated. Acceptable step-therapy agents on most Aetna plans include generic zolpidem (5 mg or 10 mg), generic trazodone (50 mg to 150 mg), or generic doxepin (3 mg to 6 mg for sleep). [7] Fourth, a clinician statement confirming the patient does not have a substance-use disorder history that would make a schedule IV controlled substance inappropriate, or a documented clinical rationale for why the benefit outweighs the risk in such patients.

PA requests submitted without all four elements have a high first-pass rejection rate. The prescriber should attach sleep-log data, any prior pharmacy fill records, and a brief clinical narrative in the initial submission rather than waiting for a denial to supply that evidence.

Step Therapy: Which Drugs Aetna Requires First

Step therapy on Aetna (CVS Health) plans for insomnia generally follows a two-step sequence. Step one requires a documented 30-day trial of a generic non-benzodiazepine sedative-hypnotic, most commonly zolpidem tartrate. Step two, in some plans, requires a second agent trial before eszopiclone is approved. [8]

Zolpidem and eszopiclone share a similar mechanism but differ in half-life and receptor-binding kinetics. Eszopiclone has a half-life of approximately 6 hours in healthy adults and up to 9 hours in elderly patients, compared to zolpidem's half-life of 1.5 to 4.5 hours. [9] For patients with sleep-maintenance insomnia rather than sleep-onset insomnia, a prescriber can use this pharmacokinetic difference as clinical justification to bypass zolpidem step therapy and request eszopiclone directly, arguing that the shorter-acting agent failed to address the specific pathophysiology.

Krystal et al. (Sleep, 2003; N=788) demonstrated that eszopiclone 3 mg significantly reduced wake time after sleep onset (WASO) by 27.5 minutes compared to placebo over six months of nightly use (P<0.001), supporting its use for sleep-maintenance insomnia specifically. [10] That trial data is directly useful in a step-therapy override letter because it provides a pharmacologically specific rationale that zolpidem's shorter duration would not replicate the WASO benefit.

Trazodone is another common step-therapy agent Aetna may require. Its sedating antihistaminergic profile is distinct from eszopiclone's GABA-A mechanism, so a trazodone failure does not pharmacologically preclude eszopiclone response. A well-written PA letter should make that distinction explicit. [11]

Documenting step-therapy failure requires more than a verbal statement. Submit pharmacy claims history showing dispense dates and day supplies, prescriber notes indicating the patient's subjective response (e.g., insufficient sleep duration, next-day sedation, or rebound insomnia on discontinuation), and any objective data such as actigraphy reports or validated questionnaire scores like the Insomnia Severity Index (ISI) or Pittsburgh Sleep Quality Index (PSQI). [12]

How to Appeal a Denied Lunesta Claim With Aetna

Aetna (CVS Health) denials for eszopiclone follow the standard multi-level appeals process required by the Affordable Care Act and state insurance regulations. The process has three usable levels before external review becomes available. [13]

Level 1: Internal First-Level Appeal. The prescriber submits a written appeal within 180 days of the denial notice. The appeal must include updated clinical documentation addressing the specific reason for denial stated in the Explanation of Benefits (EOB). Aetna is required to complete a standard appeal within 30 calendar days for non-urgent requests and within 72 hours for urgent or expedited requests. Most sleep-medication denials are non-urgent.

Level 2: Internal Second-Level Appeal. If the first-level appeal is denied, a second internal review is available. At this stage, requesting a peer-to-peer phone call between the prescribing physician and Aetna's medical director is often the most effective intervention. The peer-to-peer call allows the prescriber to present clinical nuance, such as a specific contraindication to step-therapy agents, that is difficult to convey in written documentation alone. [14]

Level 3: External Independent Review. After exhausting internal appeals, the member or prescriber may request an independent external review by a third-party organization. Under the ACA, the external reviewer's decision is binding on the insurer. External reviews for sleep medications have a meaningful overturn rate when the prescriber has submitted complete pharmacokinetic justification and documented step-therapy failure. [15]

A practical appeals framework for eszopiclone denials runs as follows. Obtain the specific denial reason code from the EOB. Match each denial code to the corresponding clinical documentation gap. Compile four items: (1) the diagnosis note with ICD-10 code, (2) pharmacy fill records from the step-therapy agents, (3) a clinical summary citing the Krystal et al. 2003 data [10] and the AASM guideline [6] to justify eszopiclone's pharmacological specificity, and (4) a signed prescriber attestation that no safer alternative is clinically appropriate. Submit all four items simultaneously rather than piecemeal.

Cost Options When Aetna Denies or Covers at High Tier

Generic eszopiclone costs approximately $15 to $20 per month at most major retail pharmacies using a GoodRx or similar discount card, which is often less than the Aetna tier-3 cost-share even when covered. For many patients, the most straightforward financial path is paying cash for generic eszopiclone rather than fighting a PA for brand-name Lunesta. [16]

Brand-name Lunesta carries a manufacturer list price near $140 per 30-day supply. Eisai, the manufacturer, has historically offered a savings program for commercially insured patients, but the program explicitly excludes members whose primary insurance is a government plan such as Medicare or Medicaid. Terms change annually, so patients should verify current eligibility directly with Eisai before relying on any coupon amount. [17]

Using a manufacturer savings card alongside an active Aetna benefit is legally permissible for commercially insured patients but is restricted under the ACA when the card is used to satisfy a deductible or out-of-pocket maximum. Aetna may decline to count manufacturer coupon payments toward the out-of-pocket accumulator, depending on the plan design. Checking the Summary of Benefits for "accumulator adjustment program" language before using a savings card is recommended. [18]

Patients who meet income criteria may qualify for Eisai's patient assistance program, which can provide brand-name Lunesta at no cost. Income thresholds and enrollment procedures are managed through the manufacturer's patient services line and through NeedyMeds.org. [19]

Clinical Background: Why Eszopiclone Gets Prescribed Over Alternatives

Eszopiclone received FDA approval on December 15, 2004, making it one of the first sleep agents approved for both sleep onset and sleep maintenance. The key trial supporting its approval showed statistically significant improvement in sleep onset latency, WASO, and total sleep time compared to placebo across a six-month treatment period. [3]

The drug's half-life of 6 hours gives it a longer effective duration than zolpidem immediate-release (half-life 1.5 to 2.5 hours) but shorter than doxepin 3 mg (half-life 15 to 17 hours). [9] This intermediate position makes eszopiclone well-suited for patients with mixed-type insomnia, meaning difficulty both initiating and maintaining sleep, who find short-acting agents insufficient and long-acting agents produce unacceptable next-day sedation. [20]

Eszopiclone 2 mg is the recommended starting dose for most adults; 3 mg is used for sleep-maintenance insomnia specifically. In patients aged 65 or older, the maximum recommended dose is 2 mg due to the extended half-life in elderly populations. [3] The FDA issued a safety communication in 2014 recommending the starting dose for all patients be reduced, consistent with updated labeling for multiple sedative-hypnotics. [21]

Chronic use beyond 12 months has been studied. Krystal et al. (Sleep, 2003) demonstrated sustained efficacy and no evidence of tolerance over six months. [10] Longer-term safety data suggest the drug is well-tolerated in appropriate candidates, though physical dependence and rebound insomnia on abrupt discontinuation remain class-level concerns shared with all non-benzodiazepine sedative-hypnotics. [22]

The AASM clinical practice guideline for chronic insomnia (2017) conditionally recommends eszopiclone as a pharmacological option for adults when CBT-I has failed or is not available. [6] That conditional recommendation, combined with the published trial data, forms the clinical backbone of any successful PA submission or appeal letter. [23]

Drug interactions require attention before prescribing. CYP3A4 inhibitors such as ketoconazole or clarithromycin can increase eszopiclone plasma levels by as much as 2.2-fold, requiring dose reduction to 1 mg. [3] CNS depressants including opioids, benzodiazepines, and alcohol compound sedation risk. Prescribers should document awareness of these interactions in the chart, as Aetna's PA form occasionally asks about concurrent CNS depressant use. [24]

What Aetna Does Not Cover: Off-Label Uses

Aetna's medical necessity criteria for eszopiclone explicitly restrict coverage to the FDA-approved indication of insomnia disorder. Coverage is not provided for prescriptions coded to anxiety disorders (F41.x), adjustment disorder with insomnia, shift-work sleep disorder, or jet lag when the underlying ICD-10 code does not include a primary insomnia diagnosis. [5]

Eszopiclone has no evidence base for weight loss, and it is not approved or used off-label for weight management. Any prescription submitted with a weight-loss indication code would be denied at adjudication. [3]

Prescribers should verify that the diagnosis code on every eszopiclone prescription maps to G47.00 (insomnia, unspecified), G47.01 (insomnia due to medical condition), or G47.09 (other insomnia) before submission. Incorrect coding is the most common avoidable reason for a first-pass denial. [25]

How to Submit an Eszopiclone PA to Aetna

Aetna accepts PA requests through three channels: the CVS Caremark online provider portal (available at caremark.com), fax using the standardized CoverMyMeds form, and phone through Aetna's pharmacy clinical team. Electronic submission through CoverMyMeds is fastest and creates a documented submission timestamp. [26]

Processing times run three to five business days for standard requests. Expedited review within 24 to 72 hours is available when the prescriber certifies that applying the standard timeframe would seriously jeopardize the patient's health or ability to regain maximum function. Sleep disorders rarely qualify for expedited review unless the prescriber documents an acute safety concern such as a commercial driver's sleep-deprivation risk or a psychiatric comorbidity. [27]

Once approved, eszopiclone PAs through Aetna are generally valid for 12 months. Re-authorization at the end of the 12-month period requires a renewal submission, though the documentation threshold is typically lower for re-authorization than for the initial PA because the prescriber can now provide 12 months of evidence of clinical response. [28]